Scientific Study Reveals E-cigarettes Can Alter Human DNA

Industry Insight by 2FIRSTS.ai
Apr.08.2024
Scientific Study Reveals E-cigarettes Can Alter Human DNA
Scientists from the University of California and the University of Innsbruck have found e-cigarettes can alter human DNA, research shows.

According to a report from Secretmag, scientists have discovered that e-cigarettes can alter human DNA. Scientists from the University of California (USA) and the University of Innsbruck (Austria) have found that changes in cheek cells are similar to those observed in regular cigarette smokers. They analyzed the epigenome, which is the information layer of DNA. Over 3,500 people participated in this new study.

 

According to Professor Martin Vidshvendtera, studying the phenotype genome of cells allows us to understand how the body responds to environmental factors such as smoking. He said, "In the same way, studying the phenotype genome can also help us predict future health conditions and diseases.

 

According to the latest scientific research, scientists have concluded through experiments that the population of people who use traditional tobacco and e-cigarettes have almost identical changes in their phenotypic genome. This phenomenon has even been observed in individuals who smoke less than 100 cigarettes. The changes in the phenotypic genome result in cancer cells growing faster within the epithelium.

 

Researchers believe that this new study confirms a theory that e-cigarettes are not as safe as the general public believes. Scientists at the University of Pittsburgh in the United States previously found that mint-flavored e-liquid is the least healthy option. This is because it produces the highest amount of toxic particles when mixed with other substances.

 

The consequences on the body include worsening lung function. Research has found that individuals who inhale menthol have less lung capacity compared to those who inhale other substances, regardless of age.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Group (Nasdaq: XXII) reported early commercial momentum for its FDA-authorized VLN® very low nicotine cigarettes, distributing approximately 8,800 cartons across 1,700 new U.S. retail outlets in the fourth quarter of 2025, while forecasting expansion to more than 5,000 retail points in 2026.
Business
Feb.24
Australian police seize tobacco and vape products in roadside stop: goods valued at A$784,950
Australian police seize tobacco and vape products in roadside stop: goods valued at A$784,950
Australian police say that during a roadside inspection in southern New South Wales, they seized 293,200 cigarettes, 265kg of hard-pressed tobacco leaf and 2,290 vape products from a van bearing Victorian number plates, with an estimated street value of A$784,950.
Feb.26 by 2FIRSTS.ai
Azerbaijan Imposes Comprehensive E-Cigarette Ban Covering Import, Export, Sales and Use, Effective April 1
Azerbaijan Imposes Comprehensive E-Cigarette Ban Covering Import, Export, Sales and Use, Effective April 1
Azerbaijan has approved amendments to its tobacco law that introduce a comprehensive ban on e-cigarettes and their components, covering import, export, production, storage, wholesale and retail sales, and use. Nicotine-containing e-cigarettes are classified as tobacco products under the revised framework. The law takes effect on April 1, 2026.
Jan.27 by 2FIRSTS.ai
Reynolds American launches U.S. investment plan: to invest $3.2 billion to expand capacity and advance a shift toward smokeless products
Reynolds American launches U.S. investment plan: to invest $3.2 billion to expand capacity and advance a shift toward smokeless products
Reynolds American says it will invest more than $3.2 billion across its U.S. operations by 2030. The investment began in 2024 and is expected to support more than 2,000 direct and indirect jobs. The company says the plan covers modernization and expansion of manufacturing facilities, scaling innovation and production, supply-chain initiatives and employee training, and also references its R&D spending and related site footprint.
Mar.06 by 2FIRSTS.ai
Product | 22ml Combined E-Liquid Supply, Rated for 35,000 Puffs: OXBAR Launches the OX35K Open-System Pod Device
Product | 22ml Combined E-Liquid Supply, Rated for 35,000 Puffs: OXBAR Launches the OX35K Open-System Pod Device
The vaping brand OXBAR has recently listed its open-system, refillable pod device OX35K on its official website. The product features a “2ml built-in pod + two 10ml external refill bottles” e-liquid supply structure and supports top refilling, with a claimed puff count of up to 35,000. It is equipped with a 1000mAh built-in battery and offers dual power modes—BOOST and ECO—positioning the device to balance high-puff performance with an open-system form factor.
Jan.13 by 2FIRSTS.ai
Special Report | New Patents Show China Tobacco Hubei Industrial Testing Gas-Releasing Nicotine Pouches
Special Report | New Patents Show China Tobacco Hubei Industrial Testing Gas-Releasing Nicotine Pouches
Newly published patent filings indicate that China Tobacco Hubei Industrial Co., Ltd., a subsidiary of China National Tobacco Corporation (CNTC), is exploring nicotine pouch technologies capable of releasing gas during oral use. The designs include carbon-dioxide microcapsules that burst in the mouth and effervescent systems that generate gas through chemical reactions with saliva, suggesting efforts to introduce new sensory dynamics into modern oral nicotine products.
News
Mar.04